MarketPulse

Type 2 diabetes

12 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Biomea Fusion to Present Icovamenib Diabetes Data at ADA Conference

Biomea Fusion selected for three late-breaking poster presentations on icovamenib at ADA 86th Scientific Sessions in June 2026, showcasing Phase 2 trial results.
BMEAPhase 2 clinical trialType 1 diabetes
BenzingaBenzinga··Vandana Singh

Novo Nordisk Advances Oral GLP-1 Therapy for Young Diabetics

Novo Nordisk reports positive phase 3a trial results for oral semaglutide in children with type 2 diabetes, planning 2026 regulatory filings for potential first pediatric GLP-1 approval.
NVOregulatory approvalOzempic
BenzingaBenzinga··Vandana Singh

Eli Lilly's Oral Weight Loss Drug Clears Cardiovascular Safety Hurdle

Eli Lilly's oral weight loss drug Foundayo met cardiovascular safety goals in Phase 3 trials, showing 57% lower mortality risk versus insulin. FDA filing planned for Q2 2026.
LLYFDA approvalweight-loss drug
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Biomea Fusion Advances Diabetes Drug With Two Phase II Studies as Treatment Gap Widens

Biomea Fusion initiates two Phase II trials of icovamenib for type 2 diabetes patients failing standard therapies, building on earlier positive data showing durable HbA1c reductions.
BMEAType 2 diabetesicovamenib
BenzingaBenzinga··Vandana Singh

Novo Nordisk Scores Historic FDA Win With First Weekly Basal Insulin

Novo Nordisk wins FDA approval for Awiqli, the first once-weekly basal insulin for Type 2 diabetes, potentially improving patient adherence and capturing significant market share.
NVOFDA approvalclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Novo Nordisk A/S

Novo Nordisk's Awiqli Wins FDA Approval as First Once-Weekly Basal Insulin for Type 2 Diabetes

FDA approves Novo Nordisk's Awiqli, the first once-weekly basal insulin for type 2 diabetes, launching in US during second half 2026 based on successful ONWARDS trials.
NVOFDA approvalType 2 diabetes
BenzingaBenzinga··Vandana Singh

Novo Nordisk's Experimental Obesity Drug Shows Superior Results to Semaglutide

Novo Nordisk and United Biotechnology's experimental drug UBT251 outperformed semaglutide in phase 2 trials, delivering stronger weight loss and glucose control.
LLYNVOweight losssemaglutide
BenzingaBenzinga··Vandana Singh

Eli Lilly's Diabetes Drug Delivers 17% Weight Loss, But Analysts Question Valuation

Eli Lilly's retatrutide shows strong weight loss results in trials, but HSBC downgrades stock citing overvaluation concerns.
LLYclinical trialweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Biomea Fusion, Inc.

Biomea Fusion's Diabetes Drug Shows Durable Benefits Nine Months Post-Dose

Biomea Fusion presents positive Phase II data for icovamenib in type 2 diabetes, showing durable 1.2% HbA1c reduction nine months after dosing with favorable safety profile.
BMEAobesityType 2 diabetes
GlobeNewswire Inc.GlobeNewswire Inc.··Cadrenal Therapeutics, Inc.

Cadrenal's Novel 12-LOX Inhibitor Shows Promise in Obesity and Diabetes Research

Cadrenal's 12-LOX inhibitor CAD-1005 shows preclinical promise for obesity and diabetes inflammation reduction, potentially complementing GLP-1 medications.
CVKDclinical developmentGLP-1 medications
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Oral GLP-1 Drug Could Reshape Weight Loss Market as Novo Nordisk Faces Competition

Eli Lilly's orforglipron oral GLP-1 drug offers no food restrictions and dual obesity-diabetes approval potential, threatening Novo Nordisk's oral Wegovy dominance.
LLYNVOpharmaceutical competitionweight-loss drug
BenzingaBenzinga··Prnewswire

Global Diabetes Survey Reveals Market Gap: 80% Demand Predictive Tools Beyond CGM

Survey of 4,326 diabetics across 22 countries shows 80% demand predictive glucose forecasting tools, revealing unmet market need beyond current continuous glucose monitoring.
RHHBYhealthcare technologyType 1 diabetes